Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: A prospective, randomized trial

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 8, 2008, Pages 2984-2990

  Carlsen, Sven M ^a,b   Lund Johansen, Morten ^c,d   Schreiner, Thomas ^e   Aanderud, Sylvi ^c   Johannesen, Øivind ^f   Svartberg, Johan ^g,h   Cooper, John G ⁱ   Hald, John K ^e   Fougner, Stine L ^e,j   Bollerslev, Jens ^e,j  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f AKER UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^h UNIVERSITY OF TROMSØ   (Norway)

ⁱ STAVANGER UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF OSLO   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CANCER INVASION; CAVERNOUS SINUS; CHRONOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES INSIPIDUS; FEMALE; FOLLOW UP; HEMATOMA; HUMAN; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; LIQUORRHEA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORWAY; NOSE DISEASE; OLFACTORY NERVE DISEASE; OPHTHALMOPLEGIA; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCREENING; SINUSITIS; STATISTICAL SIGNIFICANCE; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; VISUAL FIELD DEFECT;

EID: 49249124995     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0315     Document Type: Article

References (34)

1. Beauregard C, Truong U, Hardy J, Serri O 2003 Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86-91
2. Orme SM, McNally RJ, Cartwright RA, Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730-2734
3. Swearingen B, Barker II FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
4. Holdaway IM, Rajasoorya RC, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
5. Freda PU 2003 How effective are current therapies for acromegaly? Growth Horm IGF Res 13(Suppl A):S144-S151
6. Nomikos P, Buchfelder M, Fahlbusch R 2005 The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152:379-387
7. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM 1999 Outcome of surgery for acromegaly - the experience of a dedicated pituitary surgeon. QJM 92:741-745
8. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM 1998 The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf) 49:653-657
9. Sheppard MC 2003 Primary medical therapy for acromegaly. Clin Endocrinol (Oxf) 58:387-399
10. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25: 102-152
11. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A 2005 A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405-4410
12. Stevenaert A, Beckers A 1996 Presurgical octreotide: treatment in acromegaly. Metabolism 45(Suppl 1):72-74
13. Abe T, Ludecke DK 2001 Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145:137-145
14. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, de Divitiis E, Lombardi G 1997 Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308-3314
15. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ 1998 Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67: 1040-1048
16. Biermasz NR, van Dulken H, Roelfsema F 1999 Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 84:3551-3555
17. Kristof RA, Stoffel-Wagner B, Klingmuller D, Schramm J 1999 Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 141:399-405
18. Massart C, Poirier JY, Jard C, Pouchard M, Vigier MP 2007 Determination of serum insulin-like growth factor-I reference values for the immunometric Cisbio method on a large number of healthy subjects: clinical utility in the follow-up of patients with treated acromegaly. Clin Chim Acta 381:176-178
19. Lundin P, Pedersen F 1992 Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 16:519-528
20. Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JA, Uitterlinden P, Hofland LJ, Lamberts SW, van der Lely AJ, de Herder WW 2005 Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 90:6480-6489
21. Barkan AL 2004 Biochemical markers of acromegaly: GH vs. IGF-I. Growth Horm IGF Res 14(Suppl A):S97-S100
22. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE 1979 Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 22:1138-1142
23. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL 2002 Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87:3537-3542
24. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ 2007 Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 67:65-70
25. Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, Cappabianca P, Lombardi G 2006 Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin Endocrinol (Oxf) 65:250-256
26. Massart C, Poirier JY 2006 Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: comparison of four immunoassays. Clin Chim Acta 373:176-179
27. Comets E, Mentré F, Grass P, Kawai R, Marbach P, Vonderscher J 2003 Population pharmacodynamic analysis of octreotide in acromegalic patients. Clin Pharmacol Ther 73:95-106
28. Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A, Sheppard M 2005 Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 45:836-844
29. Chen T, Miller TF, Prasad P, Lee J, Krauss J, Miscik K, Kalafsky G, McLeod JF 2000 Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. J Clin Pharmacol 40:475-481
30. Stewart PM, Stewart SE, Clark PM, Sheppard MC 1999 Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin Endocrinol (Oxf) 50:295-299
31. Turner HE, Thornton-Jones VA, Wass JA 2004 Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf) 61:224-231
32. Lorcy Y, Dejager S, Chanson P, French Octreotide LAR Group 2000 Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly. Pituitary 3:193-197
33. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A 2005 Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737-740
34. Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K, Maiter D 2007 AcroBel-the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 157:399-409